MoneyTree™ Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

February 2014
  • Print-friendly version
MoneyTree™ Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

At a glance

On a quarterly basis, sector performance improved. During the fourth quarter of 2013, investment in the sector rose 19% to $1.8 billion from $1.5 billion during the third quarter. The number of life science deals rose 21%, from 188 during the third quarter to 228 during the final quarter of 2013. However, on a year-over-year basis, quarterly performance declined 10% in value with a 3% uptick in volume.

Regional funding trends: San Francisco Bay, Boston, Seattle, San Diego Metro, and New York Metro received the most life sciences venture capital dollars during the fourth quarter of 2013. The leader, San Francisco Bay, received $550 million in funding, with $428 million going into biotechnology, and the remaining $122 million going into medical devices. San Francisco Bay closed 54 deals during the final quarter of 2013, with an average size of $10.2 million. Boston, the runner-up, captured $356 million in biotechnology funding and $26 million in medical device funding in the final quarter of 2013.

Further reading

MoneyTree™ venture capital funding: Falling behind
MoneyTree™ venture capital funding: Biotech boost
MoneyTree™ venture capital funding: Capital crunch
MoneyTree™ venture capital funding: Biotech bounce